Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market.

The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported by joint marketing based on deep ADC expertise.

SK pharmteco and LOTTE BIOLOGICS have announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the global antibody-drug conjugate (ADC) market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029483889/en/

Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol Shin, CSO, LOTTE BIOLOGICS; James Park, CEO, LOTTE BIOLOGICS; Joerg Ahlgrimm, CEO, SK pharmteco; Andy Fenny, CCO, SK pharmteco; Olivia Boyce, Global Head of Proposals, SK pharmteco; Shiuk Lee, CSO, SK pharmteco; Steve Barr, Head of Small Molecule, SK pharmteco.

Through this collaboration, the two companies will jointly investigate providing integrated, one-stop CDMO services to global clients, offering differentiated ADC solutions that span from development to commercial manufacturing.

LOTTE BIOLOGICS will utilize its cGMP manufacturing capabilities and global quality competitiveness at its Syracuse Bio Campus in the U.S. to deliver high-quality bioconjugation and drug substance manufacturing services.

Meanwhile, SK pharmteco will be responsible for linker–payload development and manufacturing within the chemical-synthesis portion of the process, complementing LOTTE BIOLOGICS’ bioconjugation and drug-substance manufacturing.

By combining technical expertise and global networks, the companies aim to create a fully integrated CDMO platform that minimizes development-to-manufacturing gaps, offers customized solutions for clients, and strengthens competitiveness in the rapidly expanding ADC sector.

They also plan to jointly pursue global marketing and client engagement to expand their customer base across key markets.

The partnership also aligns with the ongoing global trend toward supply chain reshoring, as each company possesses advanced manufacturing infrastructures in both the U.S. and Europe.

Joerg Ahlgrimm, CEO of SK pharmteco, stated, “This strategic partnership will supercharge the development of next-generation therapeutics, positioning both companies to deliver significantly greater value and accelerate the delivery of innovative new medicines to patients around the world.”

James Park, CEO of LOTTE BIOLOGICS, added, “This collaboration marks a meaningful milestone, as two leading Korean biopharma companies join forces on the global stage. By combining our strengths in advanced modalities such as ADCs, we will reinforce Korea’s biopharmaceutical leadership and accelerate our growth in the global market.”

About SK pharmteco

SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.

About LOTTE BIOLOGICS

Headquartered in Seoul, South Korea, LOTTE BIOLOGICS was founded in 2022 with a mission to deliver therapies that contribute to a healthier world. At the Syracuse Bio Campus in New York, LOTTE BIOLOGICS provides high-quality GMP manufacturing services for drug substances. LOTTE BIOLOGICS is also advancing into a new area of expertise with Antibody-Drug Conjugates (ADCs) conjugation services. With over $100 million invested in ADC modalities, including both drug substance and conjugation capabilities on-site, we offer a seamless, end-to-end service from drug substance manufacturing to conjugation. Looking ahead, LOTTE BIOLOGICS is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2027.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251029483889/en/

Keith Bowermaster, APR, CCMP
Communications Consultant
keith.bowermaster@skpt.com

Sangho Lee, Global PR
PR Manager
Sangho.1ee@lotte.net

Logo

Images

Tags

More Like This

LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma

LOTTE BIOLOGICS establishes contract manufacturing partnership with a leading U.S. Biopharmaceutical Company

LOTTE BIOLOGICS Holds Groundbreaking for Songdo Bio Campus

Rakuten Medical and LOTTE Biologics Sign Manufacturing Agreement to Support Biopharmaceuticals in Global Oncology Program

LOTTE Holdings establishes a new Healthcare and Biopharmaceutical Corporate Venture Capital

LOTTE Biologics to Participate in DCAT Week 2026 in New York to Explore Global Partnership Opportunities

SK pharmteco Unites Leading Brands to Create Global Powerhouse in CDMO Services

Thousand Oaks Biologics Showcases Integrated ADC CRDMO Solutions & Media Innovation for Industrialization at CPHI Frankfurt 2025